2/25
09:00 am
bntx
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Low
Report
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
2/24
06:45 am
bntx
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
Low
Report
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
2/2
07:00 am
bntx
BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $113.00 price target on the stock.
1/30
02:18 am
bntx
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]
Low
Report
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline [Yahoo! Finance]
1/28
08:00 am
bntx
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Low
Report
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
1/23
09:18 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at Berenberg Bank.
1/16
07:05 am
bntx
BioNTech (NASDAQ:BNTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
Low
Report
BioNTech (NASDAQ:BNTX) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.
1/14
04:31 am
bntx
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]
Low
Report
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan [Yahoo! Finance]
1/12
07:05 am
bntx
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
06:45 am
bntx
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
12/18
04:45 am
bntx
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
Low
Report
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
12/11
07:03 pm
bntx
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
Low
Report
BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]
12/11
10:04 am
bntx
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/11
09:18 am
bntx
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
Low
Report
BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.
12/9
08:10 am
bntx
BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.
Low
Report
BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.
12/9
07:00 am
bntx
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Low
Report
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
12/6
03:30 pm
bntx
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Low
Report
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer